FLNA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Filana Therapeutics, Inc (FLNA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The company is undergoing rebranding, has profitability challenges, and lacks significant positive trading trends or catalysts. The absence of proprietary trading signals further supports a cautious approach.
The stock closed at $1.9793, down 6.70% during the regular market session, with a slight recovery of 1.50% in the post-market. The pre-market change was 0.48%. Overall, the price trend is weak, and no significant upward momentum is observed.
The company plans to rebrand as Filana Therapeutics, which could enhance market recognition and attract investor interest in the long term.
The company reported a Q4 GAAP EPS of -$0.26, indicating ongoing profitability issues. Cash reserves are projected to decrease significantly by mid-2026, and a potential litigation settlement payment of $31.25 million could further strain finances.
The company ended 2025 with $95.5 million in cash but expects to reduce this to $47-$50 million by June 30, 2026. Estimated cash use for operations in the first half of 2026 is $14-$17 million, plus a $31.25 million litigation settlement payment. Profitability remains a challenge.
No data available for analyst rating or price target changes.
